Michael Pfreundschuh

Michael Pfreundschuh pioneered dose-dense CHOP-14 chemotherapy and contributed to landmark MInT trial establishing R-CHOP as standard frontline therapy for DLBCL in younger patients. His work on optimizing CHOP backbone treatment and incorporating rituximab into DLBCL treatment has been foundational — R-CHOP (rituximab plus CHOP chemotherapy) remains the standard of care for newly diagnosed DLBCL decades after its establishment, curing approximately 60% of patients.